Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen.

This interesting clinical trial compares the addition of aflibercept, a vascular endothelial growth factor (VEGF)A and VEGFB inhibitor, to fluorouracil, leucovorin, and irinotecan (FOLFIRI) regimen as a second-line therapy for patients already treated with oxaliplatin-based chemotherapy. This randomized control trial demonstrated an improvement in both overall survival and progression-free survival in patients receiving aflibercept...

To read the rest of this recommendation and access
over 145,000 article recommendations from 3,700+ journals across biomedicine, register
for a month’s FREE TRIAL and create your
personalized F1000Prime homepage.

Institutional Subscriptions

Send a recommendation to your institution's librarian or
information manager to request an extended free trial for all users at your institution.

What is F1000Prime?

Over 145,000 recommendations of top articles in biology and medicine, contributed by the F1000 Faculty.

Covering more than 3,700 peer-reviewed journals and updated daily, the data are easily navigated by subject area or advanced search.

Unique tools allow creation of highly personalized article feeds and alerts to provide users with the most relevant and up-to-date content from F1000Prime and PubMed too.

The Faculty

The F1000 Faculty selects, rates, and reviews articles they consider worthy of inclusion in F1000Prime to help you filter the mass of biomedical literature.

It comprises more than 5,000 expert scientists and clinical researchers nominated by their peers, and includesNobel Laureates, Lasker Award winners and Fellows of the Royal Society.

Customize F1000Prime

Personalized homepage: for quick access to the most relevant F1000Prime article recommendations, plus relevant articles as soon as they are published.